Israel seeks first excessive pricing penalty
Israel’s Competition Authority plans to fine a pharmaceutical company €2.3 million for charging excessive prices for a life-saving genetic disorder medication, which would mark the first time the enforcer has issued sanctions for such an infringement.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.